Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Viatris ( (VTRS) ) has provided an announcement.
On May 7, 2026, Viatris reported first-quarter 2026 results showing total revenues of $3.52 billion, up 8% year-on-year on a reported basis and 3% operationally, with U.S. GAAP net earnings of $176 million and adjusted EBITDA of $1.0 billion, up 10% operationally, reflecting solid operating leverage. Growth was driven by strong performances in Greater China and North America, double-digit branded sales growth and new launches including Effexor in Japan, while the company reaffirmed its 2026 financial guidance and highlighted more than $2.5 billion of expected cash available for deployment this year, underscoring balance-sheet flexibility for its capital allocation plans.
The most recent analyst rating on (VTRS) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Viatris stock, see the VTRS Stock Forecast page.
Spark’s Take on VTRS Stock
According to Spark, TipRanks’ AI Analyst, VTRS is a Neutral.
The score is held back primarily by weak profitability (deep 2025 losses and negative P/E) despite solid and stable cash flow. Technicals are supportive due to a strong uptrend, but momentum is overbought, limiting the technical score. Guidance and corporate actions (cost-savings program and Biocon stake sale) are constructive, though near-term margin pressure, manufacturing disruption risk, and sizable one-time restructuring costs temper the outlook.
To see Spark’s full report on VTRS stock, click here.
More about Viatris
Viatris Inc. is a global pharmaceutical company that develops, manufactures and distributes branded and generic medicines across developed and emerging markets, including Greater China, North America, Japan and other regions. Its diversified portfolio spans brands such as Effexor for generalized anxiety disorder, alongside a broad generics franchise, positioning the group as a major player in accessible, off-patent and established therapies worldwide.
Average Trading Volume: 10,946,214
Technical Sentiment Signal: Buy
Current Market Cap: $18.57B
See more data about VTRS stock on TipRanks’ Stock Analysis page.